Summit, Evolva, PerkinElmer, Thermo Fisher, Gov. Deval Patrick | GenomeWeb
Summit and Evolva Ink Deal to Develop New Antimicrobials
 
Summit, formerly VASTox, announced this week that it has signed a three-year collaborative agreement with Basel, Switzerland-based Evolva Biotech to develop new drugs for infectious diseases.
 
The collaboration covers Oxford, UK-based Summit’s immunomodulator drug candidate SMT14400 (formerly VOX 14400) and backup compounds from the company’s proprietary imino sugar library.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.